Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of adefovir (ADV) in preventing
de novo Hepatitis B in patients who receive Hepatitis B core antibody (HBcAb) positive grafts
but who are not Hepatitis B Surface antigen (HBsAg) positive prior to transplant (Hepatitis B
naive patients). The second objective is to evaluate the efficacy of accelerated vaccination
with Hepatitis B in inducing innate immunity, thereby obviating the need for life-long
antiviral therapy.